Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Editorial

  • Editorial
    A Message from the New Editor-in-Chief
    George C. Prendergast
    Cancer Res January 1 2010 70 (1) 1-3; DOI:10.1158/0008-5472.CAN-09-4246

Reviews

  • Reviews
    Obesity and Breast Cancer: Progress to Understanding the Relationship
    Kristy A. Brown and Evan R. Simpson
    Cancer Res January 1 2010 70 (1) 4-7; DOI:10.1158/0008-5472.CAN-09-2257

    AMP kinase, a master regulator of cellular energy metabolism, may provide a key link between obesity-associated inflammation and increased breast cancer risk.

  • Reviews
    The Nicotinamide Phosphoribosyltransferase: A Molecular Link between Metabolism, Inflammation, and Cancer
    Mara Gallí, Frédéric Van Gool, Anthony Rongvaux, Fabienne Andris and Oberdan Leo
    Cancer Res January 1 2010 70 (1) 8-11; DOI:10.1158/0008-5472.CAN-09-2465

    NAMPT has properties of a positive biological modifier of NAD-dependent inflammation and cell growth that prompt interest in it as a pharmacological target for cancer treatment.

Meeting Reports

  • Meeting Reports
    Systems Biologists Seek Fuller Integration of Systems Biology Approaches in New Cancer Research Programs
    Olaf Wolkenhauer, Charles Auffray, Simone Baltrusch, Nils Blüthgen, Helen Byrne, Marta Cascante, Andrea Ciliberto, Trevor Dale, Dirk Drasdo, David Fell, James E. Ferrell Jr., Daniel Gallahan, Robert Gatenby, Ulrich Günther, Brian D. Harms, Hanspeter Herzel, Christian Junghanss, Manfred Kunz, Ingeborg van Leeuwen, Philippe Lenormand, Francis Levi, Michael Linnebacher, John Lowengrub, Philip K. Maini, Arif Malik, Katja Rateitschak, Owen Sansom, Reinhold Schäfer, Karsten Schürrle, Christine Sers, Santiago Schnell, Darryl Shibata, John Tyson, Julio Vera, Michael White, Boris Zhivotovsky and Robert Jaster
    Cancer Res January 1 2010 70 (1) 12-13; DOI:10.1158/0008-5472.CAN-09-2676

    This meeting report summarizes discussions among systems biologists concerning how to achieve greater integration of approaches in the field with the mainstream of cancer research.

  • Meeting Reports
    Twenty-First Annual Pezcoller Symposium: Unconventional Therapeutic Targets in Cancer
    Enrico Mihich, Pier Paolo Pandolfi and David Livingston
    Cancer Res January 1 2010 70 (1) 14-17; DOI:10.1158/0008-5472.CAN-09-3368

Priority Reports

  • Priority Reports
    Genetically Engineered Salmonella typhimurium as an Imageable Therapeutic Probe for Cancer
    Vu H. Nguyen, Hyung-Seok Kim, Jung-Min Ha, Yeongjin Hong, Hyon E. Choy and Jung-Joon Min
    Cancer Res January 1 2010 70 (1) 18-23; DOI:10.1158/0008-5472.CAN-09-3453

    Study describes a creative new biological approach to image and treat metastatic disease.

  • Priority Reports
    A Novel Mouse Model for De novo Melanoma
    Mayuko Y. Kumasaka, Ichiro Yajima, Khaled Hossain, Machiko Iida, Toyonori Tsuzuki, Tamio Ohno, Masahide Takahashi, Masashi Yanagisawa and Masashi Kato
    Cancer Res January 1 2010 70 (1) 24-29; DOI:10.1158/0008-5472.CAN-09-2838

    Decreased Endothelin receptor B signals facilitate de novo melanomas that do not arise from nevi.

  • Priority Reports
    Matrix Metalloproteinase-7 and Premalignant Host Responses in Helicobacter pylori–Infected Mice
    Seth R. Ogden, Jennifer M. Noto, Shannon S. Allen, Dilan A. Patel, Judith Romero-Gallo, M. Kay Washington, Barbara Fingleton, Dawn A. Israel, Nuruddeen D. Lewis, Keith T. Wilson, Rupesh Chaturvedi, Zhiguo Zhao, Yu Shyr and Richard M. Peek Jr.
    Cancer Res January 1 2010 70 (1) 30-35; DOI:10.1158/0008-5472.CAN-09-2899

    Eradication of H. pylori infections in stomach has been associated with an increased incidence of upper GI cancers, perhaps as a result of a greater incidence of gastric inflammation normally reduced by an H. pylori-induced extracellular protease.

Clinical Studies

  • Clinical Studies
    Evaluation of MicroRNA Expression Profiles That May Predict Recurrence of Localized Stage I Non–Small Cell Lung Cancer after Surgical Resection
    Santosh K. Patnaik, Eric Kannisto, Steen Knudsen and Sai Yendamuri
    Cancer Res January 1 2010 70 (1) 36-45; DOI:10.1158/0008-5472.CAN-09-3153

    Improving the ability to predict relapse of localized lung adenocarcinoma after surgical resection, through the miRNA expression profiling methods reported in this study, may alter therapeutic decisions and improve patient outcomes.

Integrated Systems and Technologies

  • Integrated Systems and Technologies
    Cancer Stem Cell Tumor Model Reveals Invasive Morphology and Increased Phenotypical Heterogeneity
    Andrea Sottoriva, Joost J.C. Verhoeff, Tijana Borovski, Shannon K. McWeeney, Lev Naumov, Jan Paul Medema, Peter M.A. Sloot and Louis Vermeulen
    Cancer Res January 1 2010 70 (1) 46-56; DOI:10.1158/0008-5472.CAN-09-3663

    Therapies that are less effective against cancer stem cells may quicken tumor evolution, increasing tumor heterogeneity and speeding the development of tumor progression and drug resistance.

Microenvironment and Immunology

  • Microenvironment and Immunology
    Insulin-Like Growth Factor-I Regulates the Liver Microenvironment in Obese Mice and Promotes Liver Metastasis
    Yingjie Wu, Pnina Brodt, Hui Sun, Wilson Mejia, Ruslan Novosyadlyy, Nomeli Nunez, Xiaoli Chen, Arnulfo Mendoza, Sung-Hyeok Hong, Chand Khanna and Shoshana Yakar
    Cancer Res January 1 2010 70 (1) 57-67; DOI:10.1158/0008-5472.CAN-09-2472

    To facilitate liver metastasis, IGF-1 must act beyond the tumor cell to provide an essential support to obesity-associated inflammatory processes in the tumor microenvironment.

  • Microenvironment and Immunology
    Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
    Minu K. Srivastava, Pratima Sinha, Virginia K. Clements, Paulo Rodriguez and Suzanne Ostrand-Rosenberg
    Cancer Res January 1 2010 70 (1) 68-77; DOI:10.1158/0008-5472.CAN-09-2587

    MDSC promote tumor formation by suppressing T cell activity through multiple mechanisms, including by blocking their essential need for cysteine.

  • Microenvironment and Immunology
    Imaging the Unfolded Protein Response in Primary Tumors Reveals Microenvironments with Metabolic Variations that Predict Tumor Growth
    Michael T. Spiotto, Alice Banh, Ioanna Papandreou, Hongbin Cao, Michael G. Galvez, Geoffrey C. Gurtner, Nicholas C. Denko, Quynh Thu Le and Albert C. Koong
    Cancer Res January 1 2010 70 (1) 78-88; DOI:10.1158/0008-5472.CAN-09-2747

    Imaging a central marker of the unfolded protein response identifies regions of tumor growth.

  • Microenvironment and Immunology
    Antigen Presentation by Dendritic Cells in Tumors Is Disrupted by Altered Metabolism that Involves Pyruvate Kinase M2 and Its Interaction with SOCS3
    Zhuohan Zhang, Qiaofei Liu, Yongzhe Che, Xin Yuan, Lingyun Dai, Bin Zeng, Guohui Jiao, Yin Zhang, Xue Wu, Yinyan Yu, Yuan Zhang and Rongcun Yang
    Cancer Res January 1 2010 70 (1) 89-98; DOI:10.1158/0008-5472.CAN-09-2970

    Metabolic aberrations in tumors affect not only tumor cells but other cell types in the tumor, including immune cells whose antigen presenting capacity becomes subverted.

  • Microenvironment and Immunology
    Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer
    Ping-Ying Pan, Ge Ma, Kaare J. Weber, Junko Ozao-Choy, George Wang, Bingjiao Yin, Celia M. Divino and Shu-Hsia Chen
    Cancer Res January 1 2010 70 (1) 99-108; DOI:10.1158/0008-5472.CAN-09-1882

    Findings define a tractable approach to degrade two important cellular mechanisms of immune suppression that are erected by advanced tumors and that inhibit the efficacy of immune stimulatory therapies.

  • Microenvironment and Immunology
    CCL2 Blockade Augments Cancer Immunotherapy
    Zvi G. Fridlender, George Buchlis, Veena Kapoor, Guanjun Cheng, Jing Sun, Sunil Singhal, M. Cecilia Crisanti, Liang-Chuan S. Wang, Daniel Heitjan, Linda A. Snyder and Steven M. Albelda
    Cancer Res January 1 2010 70 (1) 109-118; DOI:10.1158/0008-5472.CAN-09-2326

    Chemokine attack may offer an effective way to degrade immune escape by tumors, heightening the antitumor response to vaccines.

  • Microenvironment and Immunology
    Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity
    Jennifer B. Jacob, Elena Quaglino, Olga Radkevich-Brown, Richard F. Jones, Marie P. Piechocki, Joyce D. Reyes, Amy Weise, Augusto Amici and Wei-Zen Wei
    Cancer Res January 1 2010 70 (1) 119-128; DOI:10.1158/0008-5472.CAN-09-2554

    A straightforward tactic to increase the effective immunogenicity of anti-cancer DNA vaccines is demonstrated.

  • Microenvironment and Immunology
    Central Role of IFNγ–Indoleamine 2,3-Dioxygenase Axis in Regulation of Interleukin-12–Mediated Antitumor Immunity
    Tao Gu, Rachael B. Rowswell-Turner, Mehmet O. Kilinc and Nejat K. Egilmez
    Cancer Res January 1 2010 70 (1) 129-138; DOI:10.1158/0008-5472.CAN-09-3170

    IFNγ, which is critical to the antitumor activity of IL-12, is also responsible for inducing the feedback inhibitory mechanisms that regulate post-IL-12 immune responses. Specifically, IFNg induces the enzyme indoleamine 2,3 dioxygenase (IDO), which in turn promotes the expansion of CD4+ CD25+ Foxp3+ T-suppressor cells, short-circuiting post-therapy antitumor T-effector activity.

Molecular and Cellular Pathobiology

  • Molecular and Cellular Pathobiology
    Nucleolar Targeting of RelA(p65) Is Regulated by COMMD1-Dependent Ubiquitination
    Hazel C. Thoms, Carolyn J. Loveridge, James Simpson, Alexandra Clipson, Karina Reinhardt, Malcolm G. Dunlop and Lesley A. Stark
    Cancer Res January 1 2010 70 (1) 139-149; DOI:10.1158/0008-5472.CAN-09-1397

    Findings define a subnuclear targeting mechanism by which the function of the NF-κB factor RelA can be switched to promote either apoptosis or survival, addressing long-standing questions about this dual nature of NF-κB in different settings, including different cancers.

  • Molecular and Cellular Pathobiology
    Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells
    Sebastian Bauer, Joshua A. Parry, Thomas Mühlenberg, Matthew F. Brown, Danushka Seneviratne, Payel Chatterjee, Anna Chin, Brian P. Rubin, Shih-Fan Kuan, Jonathan A. Fletcher, Stefan Duensing and Anette Duensing
    Cancer Res January 1 2010 70 (1) 150-159; DOI:10.1158/0008-5472.CAN-09-1449

    Results rationalize the clinical evaluation of bortezimib (Velcade) to treat imatinib-resistant GIST tumors.

  • Molecular and Cellular Pathobiology
    Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in Osteosarcoma
    Ivan Pasic, Adam Shlien, Adam D. Durbin, Dimitrios J. Stavropoulos, Berivan Baskin, Peter N. Ray, Ana Novokmet and David Malkin
    Cancer Res January 1 2010 70 (1) 160-171; DOI:10.1158/0008-5472.CAN-09-1902

    A chromosomal region commonly deleted in osteosarcoma contains a novel group of cooperatively acting tumor suppressors, possibly with significance in other tumors as well.

  • Molecular and Cellular Pathobiology
    Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3τ and CD44 That Affect Sarcoma Incidence and Survival
    Alexei Vazquez, Lukasz F. Grochola, Elisabeth E. Bond, Arnold J. Levine, Helge Taubert, Thomas H. Müller, Peter Würl and Gareth L. Bond
    Cancer Res January 1 2010 70 (1) 172-180; DOI:10.1158/0008-5472.CAN-09-2218

    SNPs in 2 of 142 genes in the p53 network may predict clinical responses in chemotherapy of soft tissue sarcomas.

  • Molecular and Cellular Pathobiology
    OTX2 Is Critical for the Maintenance and Progression of Shh-Independent Medulloblastomas
    David C. Adamson, Qun Shi, Matthew Wortham, Paul A. Northcott, Chunhui Di, Christopher G. Duncan, Jianjun Li, Roger E. McLendon, Darell D. Bigner, Michael D. Taylor and Hai Yan
    Cancer Res January 1 2010 70 (1) 181-191; DOI:10.1158/0008-5472.CAN-09-2331

    Findings define the developmental transcription factor OTX2 as a central oncogenic driver in medulloblastoma.

  • Molecular and Cellular Pathobiology
    ZBRK1 Acts as a Metastatic Suppressor by Directly Regulating MMP9 in Cervical Cancer
    Li-Fang Lin, Chih-Hung Chuang, Chien-Feng Li, Ching-Chun Liao, Chun-Pei Cheng, Tian-Lu Cheng, Meng-Ru Shen, Joseph T. Tseng, Wen-Chang Chang, Wen-Hwa Lee and Ju-Ming Wang
    Cancer Res January 1 2010 70 (1) 192-201; DOI:10.1158/0008-5472.CAN-09-2641

    Transcriptional repressor ZBRK1 upregulated by BRCA1 has properties that may offer new insights into metastasis susceptibility in cervical carcinomas.

  • Molecular and Cellular Pathobiology
    VentX, a Novel Lymphoid-Enhancing Factor/T-Cell Factor–Associated Transcription Repressor, Is a Putative Tumor Suppressor
    Hong Gao, Yi Le, Xiaoming Wu, Leslie E. Silberstein, Roger W. Giese and Zhenglun Zhu
    Cancer Res January 1 2010 70 (1) 202-211; DOI:10.1158/0008-5472.CAN-09-2668

    Attenuations in the expression of a novel LEF/TCF pathway effector in hemtopoeitic cells might contribute to the development of chronic lymphocytic leukemia (CLL).

  • Molecular and Cellular Pathobiology
    The Aryl Hydrocarbon Receptor Functions as a Tumor Suppressor of Liver Carcinogenesis
    Yunxia Fan, Gregory P. Boivin, Erik S. Knudsen, Daniel W. Nebert, Ying Xia and Alvaro Puga
    Cancer Res January 1 2010 70 (1) 212-220; DOI:10.1158/0008-5472.CAN-09-3090

    Receptors that are well known to bind and respond to environmental toxins may also exert important unrelated functions in tumor suppression.

  • Molecular and Cellular Pathobiology
    Changes in the Mouse Estrus Cycle in Response to Brca1 Inactivation Suggest a Potential Link between Risk Factors for Familial and Sporadic Ovarian Cancer
    Hao Hong, Hai-Yun Yen, Amy Brockmeyer, Ying Liu, Rajas Chodankar, Malcolm C. Pike, Frank Z. Stanczyk, Robert Maxson and Louis Dubeau
    Cancer Res January 1 2010 70 (1) 221-228; DOI:10.1158/0008-5472.CAN-09-3232

    Groundbreaking findings identify a similar fundamental risk factor underlying sporadic and familial forms of ovarian cancer.

  • Molecular and Cellular Pathobiology
    Alternative Splicing of the Cyclin D1 Proto-Oncogene Is Regulated by the RNA-Binding Protein Sam68
    Maria Paola Paronetto, Manuela Cappellari, Roberta Busà, Simona Pedrotti, Roberta Vitali, Clay Comstock, Terry Hyslop, Karen E. Knudsen and Claudio Sette
    Cancer Res January 1 2010 70 (1) 229-239; DOI:10.1158/0008-5472.CAN-09-2788

    Functional alterations in RNA splicing that may occur widely in cancer are known to have significance for certain oncogenes and tumor suppressor genes, but the molecular basis for these alterations is only recently emerging as addressed in this study of cyclin D1 in prostate cancer.

  • Molecular and Cellular Pathobiology
    ErbB3 Binding Protein 1 Represses Metastasis-Promoting Gene Anterior Gradient Protein 2 in Prostate Cancer
    Yuexing Zhang, Tehmina Z. Ali, Hua Zhou, David R. D'Souza, Yan Lu, Jonathan Jaffe, Zhenqiu Liu, Antonino Passaniti and Anne W. Hamburger
    Cancer Res January 1 2010 70 (1) 240-248; DOI:10.1158/0008-5472.CAN-09-2904

    Metastatic prostate cancer is sustained by a possible ErbB3 signaling pathway leading through FoxA to the developmental gene AGR2, offering a new realm for therapeutic explorations against this deadly disease.

Prevention and Epidemiology

  • Prevention and Epidemiology
    Diagnosing Cervical Cancer and High-Grade Precursors by HPV16 Transcription Patterns
    Markus Schmitt, Véronique Dalstein, Tim Waterboer, Christine Clavel, Lutz Gissmann and Michael Pawlita
    Cancer Res January 1 2010 70 (1) 249-256; DOI:10.1158/0008-5472.CAN-09-2514

    Molecular diagnostics that could improve primary screening and triage of cervical lesions are described.

Therapeutics, Targets, and Chemical Biology

  • Therapeutics, Targets, and Chemical Biology
    Sodium Orthovanadate Inhibits p53-Mediated Apoptosis
    Akinori Morita, Shinichi Yamamoto, Bing Wang, Kaoru Tanaka, Norio Suzuki, Shin Aoki, Azusa Ito, Tomohisa Nanao, Soichiro Ohya, Minako Yoshino, Jin Zhu, Atsushi Enomoto, Yoshihisa Matsumoto, Osamu Funatsu, Yoshio Hosoi and Masahiko Ikekita
    Cancer Res January 1 2010 70 (1) 257-265; DOI:10.1158/0008-5472.CAN-08-3771

    Vanadate is commonly employed as an inhibitor of protein tyrosine phosphatases but it is also a potent inhibitor of p53 mediated apoptosis.

  • Therapeutics, Targets, and Chemical Biology
    Small-Molecule Inhibitors of Phosphatidylinositol 3-Kinase/Akt Signaling Inhibit Wnt/β-Catenin Pathway Cross-Talk and Suppress Medulloblastoma Growth
    Ninib Baryawno, Baldur Sveinbjörnsson, Staffan Eksborg, Ching-Shih Chen, Per Kogner and John Inge Johnsen
    Cancer Res January 1 2010 70 (1) 266-276; DOI:10.1158/0008-5472.CAN-09-0578

    New strategies to treat a common and deadly pediatric brain tumor are suggested by findings that PI3K/Akt signaling is needed to support β-catenin pathways that are known to mediate tumor cell proliferation and survival.

  • Therapeutics, Targets, and Chemical Biology
    α2-Macroglobulin Inhibits the Malignant Properties of Astrocytoma Cells by Impeding β-Catenin Signaling
    Inge Lindner, Nasr Y.A. Hemdan, Martin Buchold, Klaus Huse, Marina Bigl, Ilka Oerlecke, Albert Ricken, Frank Gaunitz, Ulrich Sack, Andreas Naumann, Margrit Hollborn, Dietmar Thal, Rolf Gebhardt and Gerd Birkenmeier
    Cancer Res January 1 2010 70 (1) 277-287; DOI:10.1158/0008-5472.CAN-09-1462

    Study of a negative modifier complex that appears to affect an important signaling pathway in brain tumors may offer a new therapeutic direction.

  • Therapeutics, Targets, and Chemical Biology
    AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
    Christine M. Chresta, Barry R. Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E. Critchlow, John P. Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini, Dominic James, Zoe Howard, Phillippa Dudley, Gareth Hughes, Lisa Smith, Sharon Maguire, Marc Hummersone, Karine Malagu, Keith Menear, Richard Jenkins, Matt Jacobsen, Graeme C.M. Smith, Sylvie Guichard and Martin Pass
    Cancer Res January 1 2010 70 (1) 288-298; DOI:10.1158/0008-5472.CAN-09-1751

    Small molecule inhibitors of the mTOR complexes represent a recent refinement of strategies to disrupt a fundamental cell growth and survival pathway for the purpose of cancer treatment.

  • Therapeutics, Targets, and Chemical Biology
    Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
    Guanglei Zhuang, Dana M. Brantley-Sieders, David Vaught, Jian Yu, Lu Xie, Sam Wells, Dowdy Jackson, Rebecca Muraoka-Cook, Carlos Arteaga and Jin Chen
    Cancer Res January 1 2010 70 (1) 299-308; DOI:10.1158/0008-5472.CAN-09-1845

    Resistance to the HER2 antibody trastuzumab, used widely in breast cancer treatment, may arise partly as a result of its ability to elevate expression of a receptor tyrosine kinase that can promote trastuzumab resistance.

  • Therapeutics, Targets, and Chemical Biology
    A Proteomic Approach for the Identification of Vascular Markers of Liver Metastasis
    Beatrice Borgia, Christoph Roesli, Tim Fugmann, Christoph Schliemann, Marta Cesca, Dario Neri and Raffaella Giavazzi
    Cancer Res January 1 2010 70 (1) 309-318; DOI:10.1158/0008-5472.CAN-09-2939

    New prognostic markers predicting metastatic spread of cancers to the liver cancer might be found among 12 vascular proteins identified in a mouse model of liver metastasis.

  • Therapeutics, Targets, and Chemical Biology
    Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
    Liewei Wang, Katarzyna A. Ellsworth, Irene Moon, Linda L. Pelleymounter, Bruce W. Eckloff, Yvette N. Martin, Brooke L. Fridley, Gregory D. Jenkins, Anthony Batzler, Vera J. Suman, Saranya Ravi, J. Michael Dixon, William R. Miller, Eric D. Wieben, Aman Buzdar, Richard M. Weinshilboum and James N. Ingle
    Cancer Res January 1 2010 70 (1) 319-328; DOI:10.1158/0008-5472.CAN-09-3224

    Personalized therapy with estrogen-lowering drugs may be advanced with findings of pharmacogenomic markers that can predict how efficiently specific patients may respond to treatment.

  • Therapeutics, Targets, and Chemical Biology
    A Gold(III) Porphyrin Complex with Antitumor Properties Targets the Wnt/β-catenin Pathway
    Kim Hei-Man Chow, Raymond Wai-Yin Sun, Janice B.B. Lam, Carrie Ka-Lei Li, Aimin Xu, Dik-Lung Ma, Ruben Abagyan, Yu Wang and Chi-Ming Che
    Cancer Res January 1 2010 70 (1) 329-337; DOI:10.1158/0008-5472.CAN-09-3324

    Novel gold compounds with cytotoxic activity based may act by altering an important class of chromatin regulators.

Tumor and Stem Cell Biology

  • Tumor and Stem Cell Biology
    Elimination of Human Lung Cancer Stem Cells through Targeting of the Stem Cell Factor–c-kit Autocrine Signaling Loop
    Vera Levina, Adele Marrangoni, Tingting Wang, Simul Parikh, Yunyun Su, Ronald Herberman, Anna Lokshin and Elieser Gorelik
    Cancer Res January 1 2010 70 (1) 338-346; DOI:10.1158/0008-5472.CAN-09-1102

    The reliance of lung cancer stem cells on c-Kit signaling suggests a possible opportunity to reposition imatinib (Gleevec) as an adjuvant to cytotoxic chemotherapy for improving lung cancer treatment.

  • Tumor and Stem Cell Biology
    Altered Expression of Neurotensin Receptors Is Associated with the Differentiation State of Prostate Cancer
    Stephanie L. Swift, Julie E. Burns and Norman J. Maitland
    Cancer Res January 1 2010 70 (1) 347-356; DOI:10.1158/0008-5472.CAN-09-1252

    A class of cell surface receptors upregulated with the acquisition of androgen independence in prostate cancer may be useful as targeting tools.

  • Tumor and Stem Cell Biology
    Prolyl Hydroxylases 2 and 3 Act in Gliomas as Protective Negative Feedback Regulators of Hypoxia-Inducible Factors
    Anne-Theres Henze, Johanna Riedel, Tanja Diem, Julia Wenner, Ingo Flamme, Jacques Pouyseggur, Karl H. Plate and Till Acker
    Cancer Res January 1 2010 70 (1) 357-366; DOI:10.1158/0008-5472.CAN-09-1876

    Findings suggest novel targets in the HIF pathway of hypoxia response that may sensitize glioblastomas to therapeutic attack.

  • Tumor and Stem Cell Biology
    Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer
    Stephen S. Myatt, Jun Wang, Lara J. Monteiro, Mark Christian, Ka-Kei Ho, Luca Fusi, Roberto E. Dina, Jan J. Brosens, Sadaf Ghaem-Maghami and Eric W-F. Lam
    Cancer Res January 1 2010 70 (1) 367-377; DOI:10.1158/0008-5472.CAN-09-1891

    FOXO1 targeting by microRNAs may mediate an important step in endometrial tumorigenesis, suggesting new tactics to restore FOXO1 expression and attack established tumors.

  • Tumor and Stem Cell Biology
    MicroRNA-145 Suppresses Cell Invasion and Metastasis by Directly Targeting Mucin 1
    Mohit Sachdeva and Yin-Yuan Mo
    Cancer Res January 1 2010 70 (1) 378-387; DOI:10.1158/0008-5472.CAN-09-2021

    Study findings confirm the importance of mucins in metastasis and offer proof of concept for use of miR-145 as a novel anti-metastatic therapy.

  • Tumor and Stem Cell Biology
    Characterization of Melanoma Cells Capable of Propagating Tumors from a Single Cell
    Matthew A. Held, David P. Curley, David Dankort, Martin McMahon, Viswanathan Muthusamy and Marcus W. Bosenberg
    Cancer Res January 1 2010 70 (1) 388-397; DOI:10.1158/0008-5472.CAN-09-2153

    Cancer stem cell theory postulates that more effective therapies will emerge only with better characterization of tumor-propagating cells that may be relatively rare in tumors, yet vital to their growth and evolution, as studied here in new models of melanoma.

  • Tumor and Stem Cell Biology
    Diagnostic and Therapeutic Potential of a Human Antibody Cloned from a Cancer Patient That Binds to a Tumor-Specific Variant of Transcription Factor TAF15
    Nicole Schatz, Stephanie Brändlein, Kilian Rückl, Frank Hensel and H. Peter Vollmers
    Cancer Res January 1 2010 70 (1) 398-408; DOI:10.1158/0008-5472.CAN-09-2186

    The capability to directly clone patient antibodies through human hybridoma technology offers a strategy to identify novel 'theranostic' markers in cancer that occur naturally during human tumorigenesis.

  • Tumor and Stem Cell Biology
    Potentiation of Temozolomide Cytotoxicity by Inhibition of DNA Polymerase β Is Accentuated by BRCA2 Mutation
    Gregory C. Stachelek, Shibani Dalal, Katherine A. Donigan, Denise Campisi Hegan, Joann B. Sweasy and Peter M. Glazer
    Cancer Res January 1 2010 70 (1) 409-417; DOI:10.1158/0008-5472.CAN-09-1353

    Findings rationalize an evaluation of patients whose tumors harbor mutations in BRCA2 for treatment with a combination of temozolomide and inhibitors of DNA polymerase β.

  • Tumor and Stem Cell Biology
    Receptor Channel TRPC6 Is a Key Mediator of Notch-Driven Glioblastoma Growth and Invasiveness
    Srinivasulu Chigurupati, Rajarajeswari Venkataraman, Daniel Barrera, Anusha Naganathan, Meenu Madan, Leena Paul, Jogi V. Pattisapu, George A. Kyriazis, Kiminobu Sugaya, Sergey Bushnev, Justin D. Lathia, Jeremy N. Rich and Sic L. Chan
    Cancer Res January 1 2010 70 (1) 418-427; DOI:10.1158/0008-5472.CAN-09-2654

    A tractable target for drug development acting downstream of Notch may yield new treatments for deadly glioblastomas.

Obituary

  • Obituary
    Barnett Rosenberg: In Memoriam (1924–2009)
    Bruce A. Chabner
    Cancer Res January 1 2010 70 (1) 428-429; DOI:10.1158/0008-5472.CAN-09-4146

Back to top
PreviousNext
Cancer Research: 70 (1)
January 2010
Volume 70, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • VentX, a Novel Lymphoid-Enhancing Factor/T-Cell Factor–Associated Transcription Repressor, Is a Putative Tumor Suppressor
  • Elimination of Human Lung Cancer Stem Cells through Targeting of the Stem Cell Factor–c-kit Autocrine Signaling Loop
  • OTX2 Is Critical for the Maintenance and Progression of Shh-Independent Medulloblastomas

Jump to

  • Editorial
  • Reviews
  • Meeting Reports
  • Priority Reports
  • Clinical Studies
  • Integrated Systems and Technologies
  • Microenvironment and Immunology
  • Molecular and Cellular Pathobiology
  • Prevention and Epidemiology
  • Therapeutics, Targets, and Chemical Biology
  • Tumor and Stem Cell Biology
  • Obituary
Advertisement
  • Most Cited
  • Most Read
Loading
  • Towards Multidrug Adaptive Therapy
  • MEK Inhibition Synergizes with Statins for Cancer Treatment
  • IL1β Promotes Immune Suppression in Pancreatic Cancer
  • Multiple Primary Cancer Penetrance for TP53
  • Metabolomic Gradients in Glioblastoma Models
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement